NSCLC Clinical Trials in Chicago, Illinois

8 studies are recruiting for nsclc in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago Medical Center ( Site 0145), Chicago, Illinois

   Locations

   216 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

2. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Center for Care and Discovery, Chicago, Illinois

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

3. A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

   The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   RUSH University Medical Center, Chicago, Illinois

   Locations

   52 in total

   Run by

   Ellipses Pharma

   See if you can join NCT05443126 on ClinicalTrials.gov

4. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

   A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University Robert H Lurie Medical Research, Chicago, Illinois

   Locations

   8 in total

   Run by

   Orano Med Theranostics, SAS

   See if you can join NCT05283330 on ClinicalTrials.gov

5. Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

   TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Memorial Hospital, Chicago, Illinois

   Locations

   18 in total

   Run by

   Tango Therapeutics, Inc.

   See if you can join NCT06922591 on ClinicalTrials.gov

6. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

   This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   12 in total

   Run by

   Vivace Therapeutics, Inc

   See if you can join NCT04665206 on ClinicalTrials.gov

7. LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients

   This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT06576635 on ClinicalTrials.gov

8. Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

   The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Jesse Brown VA Medical Center, Chicago, IL, Chicago, Illinois

   Locations

   4 in total

   Run by

   VA Office of Research and Development

   See if you can join NCT06671613 on ClinicalTrials.gov